{
}
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros, following the anticipated sale of a majority stake in its consumer division, Opella. Analyst Jo Walton expressed approval for the increased clarity surrounding the divestiture, with Sanofi expecting cash proceeds in the high single-digit billion euro range.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros, following the announcement of the planned sale of a majority stake in its consumer division, Opella. Analyst Jo Walton expressed optimism about the increased clarity regarding the divestiture, which is expected to yield cash proceeds in the high single-digit billion range.
UBS has maintained a 'Neutral' rating for GSK, setting a target price of 1580 pence ahead of the third quarter results. Analyst Jo Walton highlighted concerns over the weak performance of GSK's vaccination business in the USA, particularly for Shingrix and Arexvy, leading to an uncertain outlook for the upcoming year.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros ahead of the company's quarterly results due on October 25. Analyst Jo Walton highlighted the importance of the ongoing success of Dupixent and the market acceptance of Beyfortus.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros ahead of the company's quarterly results due on October 25. Analyst Jo Walton emphasized the importance of assessing the sustainability of Dupixent's success and the market acceptance of Beyfortus.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros ahead of the quarterly results due on October 25. Analyst Jo Walton will focus on the sustainability of Dupixent's success and the market acceptance of Beyfortus.
Jo Walton
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for sanofi with target price of 110 euros
15:36 21.10.2024
UBS maintains buy rating for Sanofi with target price of 110 euros
14:49 21.10.2024
ubs maintains neutral rating for gsk with target price of 1580 pence
11:29 21.10.2024
ubs maintains buy rating for sanofi with target price of 110 euros
13:31 17.10.2024
ubs maintains buy rating for sanofi with target price of 110 euros
12:43 17.10.2024
ubs maintains buy rating for sanofi ahead of quarterly results
12:43 17.10.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Central Bank Actions
Finance Mergers & Acquisitions
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Government Economic Policies
CEO Changes
Market Analysis and Predictions
Domestic Politics
Government Policies
Workplace Trends
GDP Growth & Recession Forecasts
Financial Scams and Security
Countries:
Companies:
Tesla, Inc.
Apple Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
Credit Suisse Strategic Income I
Banco Santander, S.A.
Berkshire Hathaway Inc.
SpaceXCoin USD
Bank of America Corporation
Morgan Stanley
BNP Paribas SA
Amazon.com, Inc.
UBS Group AG
Lloyds Banking Group plc
NVIDIA Corporation
Bank Frick AG
Citigroup Inc.
Wells Fargo & Company
Currencies:
United States Dollar
Euro
British Pound Sterling
Japanese Yen
Swiss Franc
Indian Rupee
Chinese Yuan
South Korean Won
Vietnamese Đồng
Canadian Dollar
Australian Dollar
Thai Baht
Indonesian Rupiah
Singapore Dollar
Mexican Peso
New Taiwan Dollar
Russian Ruble
Hong Kong Dollar
Offshore Chinese Yuan
New Zealand Dollar
People: